Indians may have to wait a while yet for Danish drug maker Novo Nordisk’s blockbuster weight loss drug Wegovy, which is not expected to hit the market this year. Wegovy, a relatively new drug approved by the US Food and Drug Administration (FDA) in June 2021, mimics the body’s GLP-1 hormone to promote a feeling of fullness, aiding those with obesity or overweight in losing weight."Regarding the timeline for launching Wegovy in India, unfortunately, it will not be this year," Karsten Munk Knudsen, Chief Financial Officer (CFO) and Executive Vice President (EVP) of Novo Nordisk’s, told Business Today. His remarks underline the strategic caution exercised by Novo Nordisk as they strive to balance expanding their market footprint with maintaining supply commitments in existing markets. The drug has seen widespread adoption fairly quickly across the US and several other countries, including Denmark, Norway, Germany, the UK, Iceland, Switzerland, UAE, and Japan.